Xiangxue Pharmaceutical (300147) — Working Capital to Net Assets Ratio
Xiangxue Pharmaceutical (300147) has a Working Capital to Net Assets ratio of 2187.6% as of June 2026. Working capital of CN¥-5.19 Billion (current assets of CN¥1.60 Billion minus current liabilities of CN¥6.79 Billion) is measured against net assets of CN¥-237.24 Million. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Xiangxue Pharmaceutical Working Capital to Net Assets (2007–2025)
This chart shows how Xiangxue Pharmaceutical's Working Capital to Net Assets ratio has evolved across 19 annual periods from 2007 to 2025. As of June 2026, the ratio stands at 2187.6%, reflecting working capital of CN¥-5.19 Billion against net assets of CN¥-237.24 Million CNY. Explore investment intensity of Xiangxue Pharmaceutical to see how much of total assets are deployed in long-term investments.
Annual Working Capital to Net Assets for Xiangxue Pharmaceutical (2007–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Xiangxue Pharmaceutical from 2007 to 2025, covering 19 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see total assets of Xiangxue Pharmaceutical.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | -10389.9% | CN¥-4.57 Billion | CN¥43.95 Million | CN¥1.61 Billion | CN¥6.17 Billion | ▼ -10127.2 pp |
| 2024 | -262.7% | CN¥-3.78 Billion | CN¥1.44 Billion | CN¥1.60 Billion | CN¥5.38 Billion | ▼ -118.4 pp |
| 2023 | -144.3% | CN¥-3.34 Billion | CN¥2.31 Billion | CN¥1.82 Billion | CN¥5.16 Billion | ▲ +3.3 pp |
| 2022 | -147.6% | CN¥-4.16 Billion | CN¥2.82 Billion | CN¥1.69 Billion | CN¥5.85 Billion | ▼ -44.9 pp |
| 2021 | -102.7% | CN¥-3.86 Billion | CN¥3.76 Billion | CN¥3.09 Billion | CN¥6.94 Billion | ▼ -87.2 pp |
| 2020 | -15.5% | CN¥-659.31 Million | CN¥4.25 Billion | CN¥3.72 Billion | CN¥4.38 Billion | ▼ -11.5 pp |
| 2019 | -4.0% | CN¥-163.28 Million | CN¥4.11 Billion | CN¥3.10 Billion | CN¥3.26 Billion | ▼ -21.3 pp |
| 2018 | 17.4% | CN¥696.15 Million | CN¥4.01 Billion | CN¥3.92 Billion | CN¥3.22 Billion | ▼ -24.8 pp |
| 2017 | 42.1% | CN¥1.64 Billion | CN¥3.88 Billion | CN¥5.07 Billion | CN¥3.44 Billion | ▲ +50.8 pp |
| 2016 | -8.7% | CN¥-320.33 Million | CN¥3.68 Billion | CN¥2.98 Billion | CN¥3.30 Billion | ▼ -52.8 pp |
| 2015 | 44.1% | CN¥1.56 Billion | CN¥3.55 Billion | CN¥2.13 Billion | CN¥563.86 Million | ▲ +38.2 pp |
| 2014 | 5.9% | CN¥110.98 Million | CN¥1.87 Billion | CN¥1.25 Billion | CN¥1.14 Billion | ▼ -22.1 pp |
| 2013 | 28.0% | CN¥479.49 Million | CN¥1.71 Billion | CN¥1.50 Billion | CN¥1.02 Billion | ▼ -36.0 pp |
| 2012 | 64.1% | CN¥984.63 Million | CN¥1.54 Billion | CN¥1.69 Billion | CN¥707.32 Million | ▲ +10.9 pp |
| 2011 | 53.1% | CN¥754.08 Million | CN¥1.42 Billion | CN¥1.05 Billion | CN¥294.42 Million | ▼ -14.8 pp |
| 2010 | 68.0% | CN¥931.54 Million | CN¥1.37 Billion | CN¥1.34 Billion | CN¥403.80 Million | ▲ +89.5 pp |
| 2009 | -21.6% | CN¥-72.80 Million | CN¥337.62 Million | CN¥218.72 Million | CN¥291.52 Million | ▲ +55.0 pp |
| 2008 | -76.6% | CN¥-150.48 Million | CN¥196.54 Million | CN¥115.51 Million | CN¥265.99 Million | ▼ -58.1 pp |
| 2007 | -18.4% | CN¥-35.26 Million | CN¥191.45 Million | CN¥101.18 Million | CN¥136.44 Million | — |